EP(4)-selective antagonist

Novel agonist of the prostaglandin PGE2 receptor EP4

Novel selective EP2 receptor agonist, inducing relaxation of smooth muscle

Highly selective agonist of prostaglandin E2 receptor (EP2)

Potent, orally available dual CysLT1 and CysLT2 receptor antagonist

Lipid A analog, inducing Th1-type immune response in tumor eradication and restoring nitric oxide production by peritoneal macrophages

Protease inhibitor

Novel enhancer of Schwann cell differentiation for treatment of peripheral nerve disorder

Novel non-ATP-competitive inhibitor of BCR-ABL, overriding imatinib resistance

Potent analogue of oncrasin-1 with antitumor activity mediated by JNK activation and STAT3 inhibition

Non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I

Novel potent DAGL inhibitor, inhibiting collagen-, but not arachidonic acid-induced aggregation and TxA2 synthesis

Phosphodiesterase III inhibitor, augmenting cerebral blood flow by a direct vasodilator effect on cerebral arteries

Novel Bruton's tyrosine kinase inhibitor, suppressing B cell and monocyte activation and ameliorates arthritis in a mouse model

Novel specific agonist of odorant receptor 895 (Olfr895)

Potent antioxidant and neuroprotectant for treatment of Parkinson's disease, reducing reactive oxygen species (ROS) levels, inhibiting extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, reducing rotenone-induced up-regulation of the proapopt

Natural inhibitor of the phosphorylation of protein kinase C ζ (PKCζ) at Thr410 site, reducing the activation of NF-κB using gain- and loss-of-function approaches in PE-treated cardiomyocytes, ameliorating pressure overload-induced cardiac hypertrophy

Dopamine antagonist as an atypical antipsychotic

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

Inhibitor of type 1 and type 2A protein phosphatases; Tumor promotor

Novel orally bioavailable potent JAK-1 inhibitor

Novel Bax activator, having greatest effect enhancing the pro-apoptotic activity of Bax with EC50 values of ∼0.1 μM and ∼0.9 μM, respectively, inducing cell death by a Bax/Bak-dependent mechanism

Novel luciferin analog, enabling both sensitive and highly resolved imaging in vivo

Novel HSF1 inhibitor for target-based cancer therapy

Novel potent O-GlcNAcase (OGA) inhibitor (IC 50 : 46 nM), increasing the level of O-GlcNAcylated protein in cells and displaying suitable pharmacokinetic properties and brain permeability

Cell-permeable, fluorescent Ca2+ indicator

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist

Novel highly potent and selective M3 muscarinic acetylcholine receptor antagonist and weak inverse agonist